key: cord-0843985-g6796wik
authors: David, Filipa; Morais, Joana Rodrigues; Beires, Francisca; Greenfield, Helena; Fernandes, Gonçalo L
title: Invasive Pulmonary Aspergillosis after COVID-19 Pneumonia
date: 2022-03-02
journal: Eur J Case Rep Intern Med
DOI: 10.12890/2022_003209
sha: 98575a0cb0a716da37bdd790d39a4f514a2dc7c5
doc_id: 843985
cord_uid: g6796wik

COVID-19 emerged in China in late 2019 and quickly spread worldwide. The severe immunomodulation and depletion of lymphocytes caused by the virus and its therapy led to an increase in the incidence of superinfections. COVID-19-associated pulmonary aspergillosis (CAPA) is a new entity with increasing incidence and high associated mortality. We present the case of a 68-year-old patient admitted to our ward after recovering from severe COVID-19 pneumonia. Due to worsening of her clinical condition, chest computed tomography was performed and a lung abscess was documented with the identification of Aspergillus niger. Despite therapy with voriconazole, the patient’s condition deteriorated, culminating in her death. LEARNING POINTS: COVID-19-associated pulmonary aspergillosis (CAPA) is a new entity with an increasing incidence. It is a serious and life-threatening complication in patients with severe COVID-19 even in the absence of the classic risk factors for invasive pulmonary aspergillosis. Clinical suspicion is crucial since a timely diagnosis and treatment have a major impact on prognosis.

LEARNING POINTS • COVID-19-associated pulmonary aspergillosis (CAPA) is a new entity with an increasing incidence. • It is a serious and life-threatening complication in patients with severe COVID-19 even in the absence of the classic risk factors for invasive pulmonary aspergillosis. • Clinical suspicion is crucial since a timely diagnosis and treatment have a major impact on prognosis.

A 68-year-old woman with vascular risk factors (arterial hypertension, hypertriglyceridemia and grade I obesity) and a week-old diagnosis of SARS-CoV-2 infection, presented to the emergency department with fever, non-productive cough and fatigue over the previous 4 days. She was apyretic, haemodynamically stable and tachypnoeic, with a diffusely diminished vesicular murmur and crackles in both lungs. Severe hypoxemic respiratory failure was documented (pO 2 /FiO 2 ratio <100). She presented a CRP of 189.90 mg/l, ferritin of 955.11 ng/ ml, LDH of 426 U/l and D-dimer level of 815.5 ng/ml as parameters predictive of a poor outcome in COVID-19. A computed tomography angiography (angio-CT) scan of the chest revealed ground-glass areas covering more than 75% of the lung parenchyma, compatible with COVID-19 pneumonia (Fig. 1) , without areas of cavitation or signs of pulmonary thromboembolism. She was admitted to the intensive care unit and underwent therapy with dexamethasone 16 mg i.v. once daily, and organ support measures, namely mechanical ventilation, with good response and no need for prone positioning. On the 8th day of hospitalization, the patient presented with a recurrence of fever, purulent bronchial secretions, and a worsening of her inflammatory parameters (Table 1) 

Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity

Invasive pulmonary aspergillosis associated with viral pneumonitis

COVID-19 associated with pulmonary aspergillosis: a literature review

Pulmonary aspergillosis: what the generalist needs to know

Invasive pulmonary aspergillosis goes viral again?